• Vaccine Ontology ID: VO_0004754
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Preparation: B aculovirus was used to develop a novel candidate vaccine for a preventive or therapeutic strategy to control PCV2 infections (Ye et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011481
• Type: DNA vaccine
• Status: Research
• ORF2 gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pCI-neo (Shen et al., 2008)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004699
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• ORF2 gene engineering:
  • Type: Recombinant vector construction
  • Description: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO; the genome of PRV attenuated vaccine and the transfer plasmid pGO were transfected by using Lipofectamine 2000 Reagent into swine testis cells for homologous recombination to obtain the recombinant PRV (Chao et al., 2014).
  • Detailed Gene Information: Click Here.
• Preparation: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO (Chao et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: BALB/c mice were immunized intramuscularly with this baculovirus (Ye et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Efficacy: The vaccination of mice with recombinant baculovirus BV-GD-ORF2 successfully induced robust Cap-protein-specific humoral and cellular immune responses (Ye et al., 2013).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: The mice in the vaccine groups were injected intramuscularly in the quadriceps with 100 µg pORF2 plasmid prepared in 100 µl PBS as follows. The mice in the pORF2 group received vaccination with pORF2 plasmid, three times every 2 weeks, whilst those in the pORF2/Cap or Cap/pORF2 group were primed with pORF2 plasmid (or Cap protein) and boosted with doses of Cap protein (or pORF2 plasmid) twice every 2 weeks (Shen et al., 2008).
• Challenge Protocol: At 16 weeks p.i., the mice were challenged intraperitoneally with 0.2 ml PCV2 inoculum (105.75 TCID50 1/ml) (Shen et al., 2008).
• Efficacy: Following virus challenge, real-time PCR and histopathological analysis confirmed that only low viral DNA loads and mild microscopic lesions appeared in pORF2-immunized mice (Shen et al., 2008).
• Host Ighg1 response
  • Description: Serum IgG1 was significantly higher in mice immunized with PCV2 DNA vaccine encoding ORF2 protein than control mice, vaccinated with the pCI-neo vector and crude lysate of E. coli strain BL21 transformed with pGEX-4T-1 were used as substitutes for pORF2 plasmid and Cap protein, respectively. The up regulation began 4 weeks after immunization (Shen et al., 2008).
  • Detailed Gene Information: Click Here.
• Host Ighv1-9 response
  • Description: Serum IgG2a was significantly higher in mice immunized with PCV2 DNA vaccine encoding ORF2 protein than control mice, vaccinated with the pCI-neo vector and crude lysate of E. coli strain BL21 transformed with pGEX-4T-1 were used as substitutes for pORF2 plasmid and Cap protein, respectively. The up regulation began 4 weeks after immunization (Shen et al., 2008).
  • Detailed Gene Information: Click Here.

Mouse Response

• Vaccination Protocol: Six week odl mice were immunized two intramuscular immunizations 4 weeks apart (Chao et al., 2014).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were then challenged with the virulent PCV2 NY strain at 8 weeks after the first immunization (Chao et al., 2014).
• Efficacy: Challenge experiments show that the recombinant virus and PCV2 inactivated vaccine could both protect the mice against PCV2 challenge, suggesting that the recombinant virus can be an excellent potential vaccine (Chao et al., 2014).